| Identification | Back Directory | [Name]
Benzenesulfonamide, 5-chloro-2-fluoro-N-[4-[4-[(trans-4-hydroxycyclohexyl)oxy]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]- | [CAS]
1628048-93-0 | [Synonyms]
SGK1-IN-4
SGK1-IN-4 (compound 17a)
Benzenesulfonamide, 5-chloro-2-fluoro-N-[4-[4-[(trans-4-hydroxycyclohexyl)oxy]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]- | [Molecular Formula]
C23H21ClFN5O4S | [MOL File]
1628048-93-0.mol | [Molecular Weight]
517.96 |
| Chemical Properties | Back Directory | [density ]
1.543±0.06 g/cm3(Predicted) | [solubility ]
DMSO : 250 mg/mL (482.66 mM; Need ultrasonic) | [form ]
Solid | [pka]
5.76±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research[1]. | [Biological Activity]
SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research[1]. | [References]
[1]. Nis Halland, et al. Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of Osteoarthritis. J Med Chem. 2022 Jan 27;65(2):1567-1584. |
|
|